Dear Editor in Chief,

With a great interest, we read a recently published paper in Frontier in Endocrinology journal by Vuolo et al., entitled "Vitamin D and Cancer" (Vuolo et al., [@B4]). They skillfully reviewed the role of vitamin D in all aspects of cancer such as cancer prevention, immune system and cancer, reverse effect of cancer on vitamin D, and vitamin D status in some important type of malignancy. This issue is a hot topic in oncology, but in this study there are some concerns which undermine the results to make a definite conclusion.

Although they concluded that "The immune system seems to represent a relevant target for the antineoplastic effects of vitamin D," (Vuolo et al., [@B4]) they did not consider anti-neoplastic role of activated form of vitamin D using for immunotherapy of cancer. It was recently shown that a group of vitamin D-binding protein (DBP) so called Gc protein is an important precursor for activating macrophage as one of the main innate immune cell for cancer immunotherapy (Nagasawa et al., [@B3]). Although the aim of the review by Vuolo et al. was the role of Vitamin D in cancer, it was confirmed that the level of vitamin D is related to Vitamin D binding proteins (Carpenter et al., [@B1]).

In normal tissue, when a neoplastic tissue is arise, DBP is naturally activated by glycosylation and transform to DBP-derived macrophage-activating factor (Gc-MAF) by b-galactosidase and sialidase of B and T cells, respectively, which can activate macrophage to phagocyte the neoplastic cells. Group-specific component protein (Gc) as DBP preserve vitamin D in body fluids and put it available for tissues. But an enzyme (a-N-acetylgalactosaminidase) produced by neoplastic cells deactivate and denaturize this factor and provide neoplastic cells to spread (Yamamoto and Naraparaju, [@B5]; Ghanei et al., [@B2]). In some clinical studies, Gc-MAF has successfully been used for prostate, colorectal, and breast cancer (Yamamoto and Suyama, [@B6]; Yamamoto et al., [@B7],[@B8]). Therefore, vitamin D has a prominent role in natural tumorocidal activity of immune system as an initial precursor.
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